Navidea Biopharmaceuticals shares are trading lower after the company announced NYSE American has commenced delisting proceedings and the company intends to appeal.
Portfolio Pulse from Benzinga Newsdesk
Navidea Biopharmaceuticals has announced that the NYSE American has started delisting proceedings against the company. Navidea intends to appeal against this decision. This news has led to a decrease in the company's share price.
July 31, 2023 | 9:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Navidea Biopharmaceuticals is facing delisting proceedings from the NYSE American. The company plans to appeal, but this news has negatively impacted its share price.
The commencement of delisting proceedings by NYSE American is a significant negative event for Navidea Biopharmaceuticals. This creates uncertainty about the company's future, which is likely to negatively impact investor sentiment and the company's share price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100